Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, announced today it has established an agreement with the Institute of Neuro Innovation (INI), an industry-leading clinic in Los Angeles focused on research, innovation, and applied neuroscience.

The agreement aligns with Aclarion's expansion strategy by bringing Nociscan to the Institute of Neuro Innovation and the multidisciplinary team led by neurosurgeon, Amir Vokshoor, MD. The agreement will enable Dr. Vokshoor and the INI team to generate real-world evidence evaluating how the unique insights provided by SPECT-CT and Nociscan may work in conjunction to enable physicians to make more precise treatment decisions for patients with chronic low back pain. SPECT-CT provides insights about bone metabolic activity while Nociscan measures pain-related chemical biomarkers inside each lumbar disc.